Newsq

Vaccine controls HIV infection
Enlarge image

ResearchSpainFrance

Vaccine controls HIV infection

03.01.2013 - Spanish and French researchers have found a therapeutic vaccine strategy to boost the immune response to HIV.

A therapeutic vaccine that uses heat-inactivated HIV appears to boost the immune response to the virus in people, reports Science Translational Medicine. The findings pave the way for the development of vaccines that could potentially control HIV replication without the need for life-long antiretroviral medication. The vaccine is made from treated dendritic cells or DCs.

When a microorganism like HIV invades the body, cells called phagocytes chop up the virus and break it into small fragments. Some of these pieces find their way into the membranes of DCs. The DCs then present the pieces of HIV to lymphocytes, white blood cells that then launch a specific immune response against the virus. The problem is that DCs can also carry a part of the infectious virus on their outer membrane. Consequently, the white blood cells can get infected and die instead of developing an immune response.

To avoid this problem, Felipe García from University of Barcelona and colleagues from CRNS Paris primed the DCs of 36 patients with heat-inactivated HIV and then delivered the DCs back into patients as a therapeutic vaccine. The exposure to inactivated HIV allows the DCs to deliver their message to the white blood cells without harming them. The researchers found that vaccine was able to stimulate a noticeable degree of immune response against HIV, and that higher responses correlated with better control of virus replication. However, it is not yet clear how much of an immune response is needed to make an effective vaccine. Importantly, the vaccine appeared to be safe and well-tolerated. The results offer evidence that future HIV vaccines could help control the virus.

Earlier in December another research team from Barcelona had presented a different strategy to prevent HIV infection of human CD4 lymphocytes. By blocking HIV entry into DCs they were able to prevent CD4 cells from viral invasion.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/vaccine-controls-hiv-infection.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE8.76 EUR2.10%
  • EPIGENOMICS5.31 EUR1.53%
  • MOLOGEN4.99 EUR1.42%

FLOP

  • SARTORIUS160.55 EUR-5.36%
  • STRATEC BIOMEDICAL46.74 EUR-3.67%
  • WILEX4.05 EUR-3.57%

TOP

  • 4SC4.66 EUR258.5%
  • SYNGENTA421.00 CHF27.3%
  • BASILEA134.80 CHF15.3%

FLOP

  • CYTOS0.62 CHF-42.6%
  • MEDIGENE8.76 EUR-29.4%
  • WILEX4.05 EUR-16.3%

TOP

  • WILEX4.05 EUR412.7%
  • 4SC4.66 EUR298.3%
  • FORMYCON27.20 EUR296.5%

FLOP

  • MOLOGEN4.99 EUR-53.8%
  • BIOFRONTERA2.30 EUR-25.8%
  • CO.DON2.85 EUR-22.6%

No liability assumed, Date: 26.05.2015